Bipolar disorder, current episode depressed, mild or moderate severity
Methodology & AI Transparency ⓘ
Bipolar disorder, current episode depressed, mild or moderate severity Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Diagnostic registry F31.30: Bipolar disorder, current episode depressed, mild or moderate severity is managed within Depression & Mood.
- 3 Typical cash cost range: Clinicians assessing Bipolar disorder, current episode depressed, mild or moderate severity focus on hypothalamic-pituitary-adrenal (HPA) axis in Bipolar disorder, current episode depressed, mild or moderate severity (F31.30: cortisol hyperactivity) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Bipolar disorder, current episode depressed, mild or moderate severity: TSH & Free in Bipolar disorder, current episode depressed, mild or moderate severity (F31.30: T4 Rule-Out) (TSH 0.8 – 2.5 mIU/L (F31.30)) and Serum Vitamin D in Bipolar disorder, current episode depressed, mild or moderate severity (F31.30: & RBC Folate).
Ask our AI Specialists anything about Bipolar disorder, current episode depressed, mild or moderate severity
What Is Bipolar disorder, current episode depressed, mild or moderate severity?
Recognized across U.S. clinical coding as F31.30 (Depression & Mood), Bipolar disorder, current episode depressed, mild or moderate severity is evaluated via validated longitudinal mood in Bipolar disorder, current episode depressed, mild or moderate severity (F31.30: rating scales (PHQ-9) to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Bipolar disorder, current episode depressed, mild or moderate severity (ICD-10 F31.30) is driven by hypothalamic-pituitary-adrenal (HPA) axis in Bipolar disorder, current episode depressed, mild or moderate severity (F31.30: cortisol hyperactivity); specialists in Depression, Bipolar & Mood Disorders monitor Serum Vitamin D in Bipolar disorder, current episode depressed, mild or moderate severity (F31.30: & RBC Folate) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Bipolar disorder, current episode depressed, mild or moderate severity (F31.30): persistent low mood, in Bipolar disorder, current episode depressed, mild or moderate severity (F31.30: emotional flatness, or)
- • Secondary Bipolar disorder, current episode depressed, mild or moderate severity clinical sign: disrupted sleep architecture [Bipolar disorder, current episode depressed, mild or moderate severity F31.30]
- • Symptom flares in Bipolar disorder, current episode depressed, mild or moderate severity correlating with TSH & Free in Bipolar disorder, current episode depressed, mild or moderate severity (F31.30: T4 Rule-Out) deviation outside TSH 0.8 – 2.5 mIU/L (F31.30)
- • Functional depression & mood impact requiring validated longitudinal mood in Bipolar disorder, current episode depressed, mild or moderate severity (F31.30: rating scales (PHQ-9) evaluation (F31.30)
Bipolar disorder, current episode depressed, mild or moderate severity Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F31.30 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: TSH & Free in Bipolar disorder, current episode depressed, mild or moderate severity (F31.30: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F31.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Bipolar disorder, current episode depressed, mild or moderate severity (F31.30: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F31.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Bipolar disorder, current episode depressed, mild or moderate severity (F31.30: Score) | < 4 (clinical remission) (F31.30) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Bipolar disorder, current episode depressed, mild or moderate severity
Treatment selection for Bipolar disorder, current episode depressed, mild or moderate severity depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bipolar disorder, current episode depressed, mild or moderate severity)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed: What a 376-Participant Study Found Conclusions: Lumateperone 42 mg significantly improved symptoms of depression and disease severity in patients with an MDE associated with bipolar I or bipolar II disorder, with or without mixed features. The Journal of clinical psychiatry • 2023-04-24 • Phase III Randomized Trial | N = 376 | 93/100 | PMID 37103915 ↗ |
| What the Latest Evidence Really Says About Efficacy of bupropion and the selective serotonin reuptake inhibitors in the 1.25+/-1.09, p=0.569), or HAM-A scores at endpoint (3.30+/-2.89 vs. Journal of psychiatric research • 2008-01-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 17631898 ↗ |
| Managing Depression: Can Sertraline on sleep architecture Make a Real Difference? (What New Research Reveals) However, the generalizability of these findings is limited because of a number of reasons. Journal of clinical psychopharmacology • 2003-12-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 14624183 ↗ |
| Can This Approach Help? Inside the Latest Research on Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in This study suggests an association of cerebrovascular risk, but not executive function or processing speed, with treatment outcome of major depression with psychotic features in older adults. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry • 2015-12-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 26560512 ↗ |
| Can This Approach Help? Inside the Latest Research on Duration of Adjunctive Antidepressant Maintenance in Bipolar I In a trial involving patients with bipolar I disorder and a recently remitted depressive episode, adjunctive treatment with escitalopram or bupropion XL that continued for 52 weeks did not show a significant benefit as... The New England journal of medicine • 2023-08-03 • Randomized Controlled Trial | N = 90 | 88/100 | PMID 37530824 ↗ |
Bipolar disorder, current episode depressed, mild or moderate severity Patient Community & “People Like Me” Threads
Filter Bipolar disorder, current episode depressed, mild or moderate severity community threads and patient logs by age, biological sex, dosage, and treatment duration.